Viiv's Dovato as Effective as Gilead' Biktarvy for HIV but With Less Weight Gain
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
Breaking Down Gilead Sciences: 10 Analysts Share Their Views
Gilead Sciences Analyst Ratings
List of stocks with cloud breakout (weekly) [Ichimoku Kinko Hyo, List of stocks with cloud breakouts]
List of stocks that broke through the clouds Market Code, Stock Name, Closing Price, Leading Span A, Leading Span B Tokyo Stock Exchange Prime Board <3087> Dotol Niless, 2288, 2199, 2112.5 <3402> Toray Industries Inc., 793, 761, 774 <3475> Goodcom A, 868, 840.75, 863 <3486> Global Lin
List of converted stocks (Part 2) [List of converted stocks for Parabolic Signal]
List of sell conversion stocks in the market. Code Company name Closing price SAR Tokyo Prime <1375> Yukiguni Maitake 1002 1028 <1605> INPEX 2420 2508 <167A> Ryosan Hiso Yo 3050 3145 <1805> Tobishima Corporation 1533 1580 <1820> Nishimatsu Construction
Here Are Big Pharma's Leading Blockbuster Makers
Check Out What Whales Are Doing With GILD
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Here's How Much $1000 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
Regeneron Pharmaceuticals Analyst Ratings
Cosmos Pharmaceuticals, 7&I-HD, etc. (additional) Rating
Target stock price change code | Stock name | Securities company | Previous | After change | ------ | ------------- | ------------- | --------- | --------- | <2802> | Ajinomoto | GS | 6800 yen | 7000 yen | <2914> | JT | GS | 4400 yen | 4600 yen | <3349> | Cosmos Pharmaceutical | Mizuho
Most Shorted S&P 500 Stocks in June
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
Incyte, Moderna Among Most Shorted S&P 500 Healthcare Stocks in June
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
Gilead Highlights Progress In Research Across HIV Prevention, Treatment And Cure Programs At AIDS 2024
Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter